Pieter Droppert writes the Biotech Strategy Blog and is a marketing strategy consultant with a focus on oncology/hematology new product development. Pieter is a Sloan Fellow from London Business School and was formerly a project manager for a major phase III drug development program at a global CRO.
Recent Articles By The Author
J&J Buy of Aragon Deals a Blow to Medivation
Medivation now has a formidable competitor for prostate cancer therapy.
Winners And Losers in CLL at ASCO '13
Drugs from Gilead Sciences and Roche stood out at ASCO this year, while Infinity's drug lagged.
Aveo's Future Depends on Triple-Negative Breast Cancer
Aveo's next chance to resurrect its flailing cancer drug will come in 2014/2015 with breast cancer study data.